Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit
- PMID: 1731324
- PMCID: PMC48271
- DOI: 10.1073/pnas.89.2.524
Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit
Abstract
Verotoxin 1 (VT-1) and Shiga-like toxin II (SLT-II) bind to the glycosphingolipid (GSL), globotriaosylceramide (Gb3), whereas pig edema disease toxin (VTE) binds to globotetraosylceramide (Gb4) and to a lesser degree Gb3. Amino acids important in the GSL binding specificity of VT-1 and VTE have been identified by site-directed mutagenesis. One mutation, Asp-18----Asn, in VT-1 resulted in binding to Gb4 in addition to Gb3 in a manner similar to VTE. Several mutations in VTE resulted in the complete loss of GSL binding; however, one mutation resulted in a change in the GSL binding specificity of the VTE B subunit. The double mutation Gln-64----Glu and Lys-66----Gln (designated GT3) caused a selective loss of Gb4 binding, effectively changing the binding phenotype from VTE to VT-1. Both wild-type VTE and GT3 were purified to homogeneity and binding kinetics in vitro were determined with purified GSLs from human kidney. The cell cytotoxicity spectrum of the mutant toxin was also found to be altered in comparison with VTE. These changes were consistent with the GSL content of the target cells.
Similar articles
-
Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs.J Exp Med. 1993 Jun 1;177(6):1745-53. doi: 10.1084/jem.177.6.1745. J Exp Med. 1993. PMID: 8496689 Free PMC article.
-
Globotetraosylceramide is recognized by the pig edema disease toxin.J Biol Chem. 1989 Jul 25;264(21):12520-5. J Biol Chem. 1989. PMID: 2663859
-
Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.Infect Immun. 1990 Mar;58(3):611-8. doi: 10.1128/iai.58.3.611-618.1990. Infect Immun. 1990. PMID: 2155181 Free PMC article.
-
Verotoxin Receptor-Based Pathology and Therapies.Front Cell Infect Microbiol. 2020 Mar 31;10:123. doi: 10.3389/fcimb.2020.00123. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32296648 Free PMC article. Review.
-
Tumor necrosis factor and interleukin 1 induce expression of the glycolipid verotoxin receptor in human endothelial cells. Implications for the pathogenesis of the haemolytic uraemic syndrome.Behring Inst Mitt. 1993 Aug;(92):202-9. Behring Inst Mitt. 1993. PMID: 8250811 Review.
Cited by
-
Development of monoclonal antibodies and immunoassays for sensitive and specific detection of Shiga toxin Stx2f.PLoS One. 2013 Sep 17;8(9):e76563. doi: 10.1371/journal.pone.0076563. eCollection 2013. PLoS One. 2013. PMID: 24069462 Free PMC article.
-
Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits.Infect Immun. 1997 Jun;65(6):2019-28. doi: 10.1128/iai.65.6.2019-2028.1997. Infect Immun. 1997. PMID: 9169727 Free PMC article.
-
Increased globotriaosylceramide on plasma membranes of synchronized familial dysautonomia cells. Verotoxin binding studies.J Mol Neurosci. 1994 Summer;5(2):121-32. doi: 10.1007/BF02736753. J Mol Neurosci. 1994. PMID: 7710921
-
Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flowcytometric application.Glycoconj J. 1999 Nov;16(11):697-705. doi: 10.1023/a:1007107425891. Glycoconj J. 1999. PMID: 11003554
-
Shiga Toxins: An Update on Host Factors and Biomedical Applications.Toxins (Basel). 2021 Mar 18;13(3):222. doi: 10.3390/toxins13030222. Toxins (Basel). 2021. PMID: 33803852 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources